Unicycive Therapeutics, Inc.

Historical 13F Holders

Symbol
UNCY
CUSIP
90466Y103
All holders as of
Q1 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 90466Y103 since 12/18/2024, newest first.

Filer % of Class Filed
Nantahala Capital Management, LLC 13G/A Amendment 8
10.0% 11/14/2025
Event 9/30/2025
Nantahala Capital Management, LLC 13G/A Amendment 7
10.0% 8/14/2025
Event 6/30/2025
RA Capital Management, L.P. 13G/A Amendment 4
9.9% 5/15/2025
Event 3/31/2025
Vivo Opportunity Fund Holdings, L.P. 13G/A Amendment 2
10.0% 5/15/2025
Event 3/31/2025
Nantahala Capital Management, LLC 13G/A Amendment 6
10.0% 5/15/2025
Event 3/31/2025
RA Capital Management, L.P. 13G/A Amendment 3
9.9% 2/14/2025
Event 12/31/2024
Great Point Partners, LLC 13G/A Amendment 2
10.0% 2/14/2025
Event 12/31/2024
Walleye Capital LLC 13G/A Amendment 1 4.8% 2/6/2025
Event 12/31/2024
Nantahala Capital Management, LLC 13G/A Amendment 5
10.0% 12/20/2024
Event 12/19/2024
Nantahala Capital Partners Limited Partnership 13G/A Amendment 2 2.8% 12/20/2024
Event 12/19/2024
Nantahala Capital Partners Limited Partnership 13G/A Amendment 1 7.8% 11/14/2024
Event 9/30/2024
Nantahala Capital Management, LLC 13G/A Amendment 4
10.0% 11/14/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q1 30 59.9 M $34.5 M
2024 Q4 32 61.7 M $49.0 M
2024 Q3 31 46.8 M $19.1 M
2024 Q2 28 25.3 M $12.7 M
2024 Q1 25 21.2 M $31.6 M
2023 Q4 19 16.6 M $14.4 M
2023 Q3 17 14.2 M $12.2 M
2023 Q2 17 1.09 M $1.40 M
2023 Q1 14 1.69 M $3.54 M
2022 Q4 10 795 k $428 k
2022 Q3 13 968 k $571 k
2022 Q2 16 1.19 M $992 k
2022 Q1 13 1.15 M $1.48 M
2021 Q4 13 1.12 M $2.30 M
2021 Q3 11 1.07 M $3.02 M